These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11057342)

  • 1. A comparison of the effects of olopatadine and ketotifen on model membranes.
    Brockman H; Graff G; Spellman J; Yanni J
    Acta Ophthalmol Scand Suppl; 2000; (230):10-5. PubMed ID: 11057342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of olopatadine and selected antihistamines with model and natural membranes.
    Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
    Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
    J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
    Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats.
    Yamada K; Takizawa F; Tamura T; Kanda T
    Biol Pharm Bull; 2012; 35(5):693-7. PubMed ID: 22687403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.
    Tashiro M; Mochizuki H; Sakurada Y; Ishii K; Oda K; Kimura Y; Sasaki T; Ishiwata K; Yanai K
    Br J Clin Pharmacol; 2006 Jan; 61(1):16-26. PubMed ID: 16390347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
    Kishimoto K; Kaneko S; Ohmori K; Tamura T; Hasegawa K
    Mediators Inflamm; 2006; 2006(1):42726. PubMed ID: 16864903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
    Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
    Cook EB; Stahl JL; Barney NP; Graziano FM
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
    Schoch C
    Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
    Lee JS; Lee JE; Kim N; Oum BS
    J Ocul Pharmacol Ther; 2008 Dec; 24(6):557-62. PubMed ID: 19049267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].
    Li J; Yan XM
    Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):43-50. PubMed ID: 20388322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists.
    Lytinas M; Kempuraj D; Huang M; Boucher W; Esposito P; Theoharides TC
    Int Arch Allergy Immunol; 2003 Mar; 130(3):224-31. PubMed ID: 12660427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
    Leonardi A; Abelson MB
    Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate.
    Logan A; Pucker AD; Franklin Q; McGwin G; Hogan C; Kelley LR; Christensen M; Brafford R; Lievens C
    Cont Lens Anterior Eye; 2023 Apr; 46(2):101769. PubMed ID: 36195538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.